Clinical guideline
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
J Clin Oncol · 2022
59 randomised trialsEvidence base
Studies and guidelines: Brain tumours
22 items with a structured summary · Brain tumours: the complete guide
Clinical guideline
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
JCO · 2022
32 randomised trials published in 2008 or laterEvidence base
Clinical guideline
EANO guideline on the diagnosis and management of meningiomas
Neuro Oncol · 2021
Clinical guideline
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Nat Rev Clin Oncol · 2021
Clinical guideline
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Ann Oncol · 2021
Clinical trial · Phase 3
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Lancet Oncol · 2026
HR 0.65Adjuvant temozolomide in all patients (overall survival)
Other
FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery
Clinical Cancer Research · 2025
HR 0.39 (95% CI 0.27 to 0.56)Radiographic progression-free survival (PFS); hazard ratio
Review article
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Neuro-Oncology · 2025
Clinical trial · Phase 3
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology · 2025
Median not reached (95% CI 22.1–not estimable) vs 11.4 months (11.1–13.9)Progression-free survival (median)
Other
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017–2021
Neuro-Oncology · 2024
25.34 per 100,000 populationOverall incidence of all primary brain and CNS tumours (AAAIR)
Review article
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
Neuro-Oncology · 2021
Clinical trial · Phase 3
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
JAMA · 2017
20.9 vs 16.0 monthsMedian overall survival
Clinical trial · Phase 3
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
N Engl J Med · 2017
9.3 vs 7.6 monthsMedian overall survival
Clinical trial · Phase 3
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial
JAMA · 2016
63.5% vs 91.7%Cognitive deterioration at 3 months
Observational study
Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study
Lancet Oncol · 2014
10.8 vs 10.8 monthsMedian overall survival (2–4 vs 5–10 tumours)
Clinical trial · Phase 3
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
The Lancet Oncology · 2009
27.2% vs 10.9%2-year overall survival
Observational study
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
N Engl J Med · 2005
45% of 206 evaluable casesFrequency of MGMT promoter methylation
Clinical trial · Phase 3
Lomustine and Bevacizumab in Progressive Glioblastoma
N Engl J Med · 2017
9.1 months vs 8.6 months (combination vs monotherapy)Median overall survival
Clinical trial · Phase 3
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
N Engl J Med · 2016
13.3 vs 7.8 yearsMedian overall survival
Clinical trial · Phase 3
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
N Engl J Med · 2023
27.7 vs 11.1 monthsMedian progression-free survival
Clinical trial · Phase 3
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Lancet Oncol · 2021
82.3 vs 46.9 monthsAdjuvant temozolomide: median overall survival
Clinical trial · Phase 3
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
N Engl J Med · 2005
14.6 vs 12.1 monthsMedian overall survival
Nothing found.